Objective: The majority of drug addicts are polydrug dependent, and no effective pharmacological treatment is currently available for them. The authors studied the overall real-world effectiveness of naltrexone implant in this patient population.

Method: The authors assessed the effectiveness of a naltrexone implant in the treatment of coexisting heroin and amphetamine polydrug dependence in 100 heroin- and amphetamine-dependent outpatients in a 10-week randomized, double-blind, placebo-controlled trial. The main outcome measures were retention in the study, proportion of drug-free urine samples, and improvement score on the Clinical Global Impressions Scale (CGI). Analyses were conducted in an intent-to-treat model.

Results: At week 10, the retention rate was 52% for patients who received a naltrexone implant and 28% for those who received a placebo implant; the proportions of drug-free urine samples were 38% and 16%, respectively, for the two groups. On the CGI improvement item, 56% of the patients in the naltrexone group showed much or very much improvement, compared with 14% of those in the placebo group (number needed to treat=3).

Conclusions: Naltrexone implants resulted in higher retention in the study, decreased heroin and amphetamine use, and improved clinical condition for patients, thus providing the first evidence of an effective pharmacological treatment for this type of polydrug dependence.
Method

Study Design

The trial was conducted at the St. Petersburg State Pavlov Medical University, Russia, and its affiliated hospital, Leningrad Regional Addiction Hospital. The recruitment of patients began in March 2008, and the study was completed in February 2011. An interim analysis of the first 50 patients was conducted to evaluate the putative harms and benefits of the interventions. Since no harmful effects were observed to be associated with the active treatment, the study was continued as planned. One hundred patients having coexisting amphetamine and opioid dependence (confirmed by a positive urine sample) were randomly assigned, in a 1:1 ratio in a double-blind protocol, to receive a naltrexone depot implant (N=50) or a placebo implant that was identical in appearance (N=50). A sample size of 100 was considered sufficient to reveal significance of an effect size of medium magnitude (20). Randomization was done with a computer-generated random number list prepared by an investigator with no clinical involvement in the trial (E.V.). The study was approved by the Independent Ethical Committee of St. Petersburg State Pavlov Medical University.

Patients

The inclusion criteria were a primary DSM-IV diagnosis of concurrent amphetamine and opioid dependence, present for at least 1 year; age between 18 and 50 years; education level of high school graduate or above; negative urine toxicology and alcohol breath tests; no current use of psychotropic medications; at least one relative willing to participate in the treatment (e.g., to monitor the administration of medications, assist in follow-up, and provide outcome data); a stable address in St. Petersburg or in the nearest districts of Leningrad Region; a home telephone number at which the patient could be reached; willingness and ability to give informed consent and otherwise participate; and, for women of childbearing age, a negative pregnancy test and use of adequate contraception.

The exclusion criteria were clinically significant cognitive impairment, schizophrenia, a paranoid disorder, bipolar disorder, or a seizure disorder; advanced neurological, cardiovascular, renal, or hepatic disease; active tuberculosis; a current febrile illness; an AIDS-defining illness; a significant laboratory abnormality, such as severe anemia, unstable diabetes, or liver function test results greater than three times normal values; pregnancy; pending legal charges with potential impending incarceration; concurrent participation in another treatment study; and concurrent treatment in another substance abuse program.

Procedure

Treatment medication was labeled according to the randomization list, and all individuals involved with the clinical phase of the trial were blind to the intervention. Patients were examined by a psychiatrist at the beginning of the study and at visits throughout treatment. Psychiatrists who were trained in individual drug counseling (E.B., O.M.) enrolled the patients, assigned them to interventions, reviewed their substance use, recovery efforts, functioning, and adverse events, and provided them with psychological support and advice. Patients had to provide an opioid-negative urine sample and undergo a naloxone challenge test, after which they received the surgical naltrexone implant. This sustained-release naltrexone preparation (Prodexton) has been approved in the Russian Federation for preventing relapse to opioid dependence. Prodexton is a composite subcutaneous implant prepared in a cylinder that is 18 mm long and 8.5 mm in diameter. It contains 1000 mg of naltrexone and blocks opioid effects for 6–10 weeks. Patients gave urine samples (the pH of the urine was measured) once a week, under supervision, for up to 70 days (10 weeks). The cutoff for heroin-free urine was 300 ng/mL of morphine. With this procedure, heroin can be detected for up to 3–4 days after use, which may result in missing occasional heroin use in weekly urine tests. Opioid and amphetamine use was also assessed by self-reported use on the timeline follow-back survey (21). The severity of the addiction at baseline was measured by the Addiction Severity Index (22). Other health assessments included the HIV Risk Assessment Battery (23), visual analogue scales of craving for opioids and amphetamine, the Clinical Global Impressions Scale (CGI), and the Global Assessment of Functioning Scale (GAF). Safety was assessed by weekly monitoring of treatment-emergent adverse events, with vital signs and biochemistry and hematology of urine and blood samples, which included liver function tests. Adverse events were assessed through open questions during the weekly visits. At week 10, participants’ relatives were contacted by telephone to investigate outcomes (including mortality) among patients who dropped out.

Outcomes

The primary outcomes assessed were retention in the study, proportion of urine samples that were free of both amphetamine and opioids during the treatment (missing samples were considered positive for both drug classes), and improvement on the CGI during treatment.

The secondary outcomes assessed were proportion of opioid-free urine samples during treatment (missing samples were considered opioid positive), proportion of amphetamine-free urine samples during the treatment (missing samples were considered amphetamine positive), GAF score, number of days per week that amphetamine was used during treatment, craving for opioids and amphetamine, and adverse events.

The study protocol was updated on December 22, 2009, for several reasons. Because of new legislation in Russia prohibiting the export of any biological samples to Finland, the quantitative amphetamine analyses could not be done in the laboratory of the National Public Health Institute, Helsinki. Also, funding was not sufficient for us to perform naloxone challenge tests to evaluate opioid dependence. Under these circumstances, we decided to use conventional urine tests to measure opioid and amphetamine use (our primary outcome measure). The updated protocol also included the addition of retention in the study and CGI improvement score as primary outcome measures (retention in the study and the patients’ general well-being are considered the most important indicators of the effectiveness of the treatment in drug addiction trials). For the secondary outcomes, the update added adverse events and excluded cannabis and benzodiazepine use, since it had become evident that their use was not sufficiently common in the study population. The original sponsor, the National Research and Development Centre for Welfare and Health (Finland), merged with the National Public Health Institute on January 1, 2009, and the organization became the National Institute for Health and Welfare; thus, the name of the sponsor changed in the update. Finally, the start and end dates were delayed from the anticipated dates.

Statistical Analysis

The results were analyzed in an intent-to-treat model in which missing urine samples were classified as drug positive. Categorical variables were analyzed with the chi-square test or Fisher’s exact test and continuous variables with the t test or Mann-Whitney U test, depending on the validity of distributional assumptions. Data management and analyses were conducted with SPSS, version 17.0 (SPSS, Inc., Chicago), and StatCalc (www.acastat.com). For patients lost to follow-up, the change in the CGI improvement score was defined as the change between baseline (week 0) and the last available observation.
Retention in the study is illustrated in Figure 1. At week 10, the retention rate was 52% (N=26) for the naltrexone group and 28% (N=14) for the placebo group (χ²=6.00, df=1, p=0.01). The proportion of drug-free urine samples was 38% (N=19) in the naltrexone group and 16% (N=8) in the placebo group (χ²=6.14, df=1, p=0.01). The changes in the CGI improvement score indicating the difference in treatment effect are summarized in Table 2. The naltrexone arm showed a substantially greater treatment effect than the placebo arm, with 56% of naltrexone patients showing much or very much improvement according to the CGI, compared with only 14% of the placebo patients (χ²=19.4, df=1, p<0.001; number needed to treat=3, 95% CI=2–4).

Secondary Outcome Measures

At week 10, patients in the naltrexone group had significantly more heroin-free urine samples (52% compared with 20%; χ²=11.1, df=1, p<0.001) and more amphetamine-free urine samples, although the difference fell short of significance (40% compared with 24%; χ²=2.94, df=1, p=0.09). In the weekly urine analyses, a statistically significant difference in heroin-free samples was also observed at week 6 (χ²=8.1, df=1, p=0.005), at week 8 (χ²=4.3, df=1, p=0.04), and at week 9 (χ²=4.2, df=1, p=0.04), with patients in the naltrexone arm having more heroin-free samples. No statistically significant differences were observed in amphetamine-free urine samples. At week 10, the mean number of amphetamine use incidents (times/week) was 4.5 times in the naltrexone group and 5.7 times in the placebo group (Mann-Whitney U test=1030.5, p=0.06). The rating of subjective effects of amphetamine was available for 18 patients in the placebo group and 22 patients in the naltrexone group. Fifteen patients in the placebo group (83.3%) and three in the naltrexone group died during the study.

Results

The CONSORT flow diagram of the study is presented in Figure S1 in the online data supplement that accompanies the online edition of this article. The main baseline clinical measures are listed in Table 1; no statistically significant differences were observed between the two treatment groups. Most patients were men; the naltrexone arm included four women (8%), and the placebo arm included seven (14%). HIV status was available for 86 patients; in the placebo arm, 77% (34/44) were HIV positive, and in the naltrexone arm, 48% (20/42) were HIV positive (χ²=8.09, df=1, p=0.004). Fifteen patients (30%) in the naltrexone group used marijuana, and 13 (26%) in the placebo group did so. The use of sedatives was rare in this sample (none in the naltrexone arm, and one in the placebo arm). The mean consumption of alcohol was only 7.5 g/day (SD=9.9) for the total study population, and therefore the putative reduction was not studied.

**Primary Outcome Measures**

The CONSORT flow diagram of the study is presented in Figure S1 in the online data supplement that accompanies the online edition of this article. The main baseline clinical measures are listed in Table 1; no statistically significant differences were observed between the two treatment groups. Most patients were men; the naltrexone arm included four women (8%), and the placebo arm included seven (14%). HIV status was available for 86 patients; in the placebo arm, 77% (34/44) were HIV positive, and in the naltrexone arm, 48% (20/42) were HIV positive (χ²=8.09, df=1, p=0.004). Fifteen patients (30%) in the naltrexone group used marijuana, and 13 (26%) in the placebo group did so. The use of sedatives was rare in this sample (none in the naltrexone arm, and one in the placebo arm). The mean consumption of alcohol was only 7.5 g/day (SD=9.9) for the total study population, and therefore the putative reduction was not studied.

**Secondary Outcome Measures**

At week 10, patients in the naltrexone group had significantly more heroin-free urine samples (52% compared with 20%; χ²=11.1, df=1, p<0.001) and more amphetamine-free urine samples, although the difference fell short of significance (40% compared with 24%; χ²=2.94, df=1, p=0.09). In the weekly urine analyses, a statistically significant difference in heroin-free samples was also observed at week 6 (χ²=8.1, df=1, p=0.005), at week 8 (χ²=4.3, df=1, p=0.04), and at week 9 (χ²=4.2, df=1, p=0.04), with patients in the naltrexone arm having more heroin-free samples. No statistically significant differences were observed in amphetamine-free urine samples. At week 10, the mean number of amphetamine use incidents (times/week) was 4.5 times in the naltrexone group and 5.7 times in the placebo group (Mann-Whitney U test=1030.5, p=0.06). The rating of subjective effects of amphetamine was available for 18 patients in the placebo group and 22 patients in the naltrexone group. Fifteen patients in the placebo group (83.3%) and three in the naltrexone group died during the study.

**Results**

The CONSORT flow diagram of the study is presented in Figure S1 in the online data supplement that accompanies the online edition of this article. The main baseline clinical measures are listed in Table 1; no statistically significant differences were observed between the two treatment groups. Most patients were men; the naltrexone arm included four women (8%), and the placebo arm included seven (14%). HIV status was available for 86 patients; in the placebo arm, 77% (34/44) were HIV positive, and in the naltrexone arm, 48% (20/42) were HIV positive (χ²=8.09, df=1, p=0.004). Fifteen patients (30%) in the naltrexone group used marijuana, and 13 (26%) in the placebo group did so. The use of sedatives was rare in this sample (none in the naltrexone arm, and one in the placebo arm). The mean consumption of alcohol was only 7.5 g/day (SD=9.9) for the total study population, and therefore the putative reduction was not studied.

**Primary Outcome Measures**

Retention in the study is illustrated in Figure 1. At week 10, the retention rate was 52% (N=26) for the naltrexone group and 28% (N=14) for the placebo group (χ²=6.00, df=1, p=0.01). The proportion of drug-free urine samples was 38% (N=19) in the naltrexone group and 16% (N=8) in the placebo group (χ²=6.14, df=1, p=0.01). The changes in the CGI improvement score indicating the difference in treatment effect are summarized in Table 2. The naltrexone arm showed a substantially greater treatment effect than the placebo arm, with 56% of naltrexone patients showing much or very much improvement according to the CGI, compared with only 14% of the placebo patients (χ²=19.4, df=1, p<0.001; number needed to treat=3, 95% CI=2–4).

**Secondary Outcome Measures**

At week 10, patients in the naltrexone group had significantly more heroin-free urine samples (52% compared with 20%; χ²=11.1, df=1, p<0.001) and more amphetamine-free urine samples, although the difference fell short of significance (40% compared with 24%; χ²=2.94, df=1, p=0.09). In the weekly urine analyses, a statistically significant difference in heroin-free samples was also observed at week 6 (χ²=8.1, df=1, p=0.005), at week 8 (χ²=4.3, df=1, p=0.04), and at week 9 (χ²=4.2, df=1, p=0.04), with patients in the naltrexone arm having more heroin-free samples. No statistically significant differences were observed in amphetamine-free urine samples. At week 10, the mean number of amphetamine use incidents (times/week) was 4.5 times in the naltrexone group and 5.7 times in the placebo group (Mann-Whitney U test=1030.5, p=0.06). The rating of subjective effects of amphetamine was available for 18 patients in the placebo group and 22 patients in the naltrexone group. Fifteen patients in the placebo group (83.3%) and three in the naltrexone group died during the study.
At week 10, retention was 52% (26/50) for patients in the naltrexone group, compared with 28% (14/50) for patients in the placebo group (significantly different at p=0.01). Since patients were permitted to continue in the trial despite missing previous visits, the retention rate increased at weeks 6 and 9, when patients who missed visits the previous week resumed participation.

Adverse Events

Adverse events are listed in Table 3. No severe adverse events were reported, and no significant differences were observed between groups. No significant differences were seen between groups in change in the alanine aminotransferase (ALT) level from baseline to week 10 (from 39.9 U/L to 36.2 U/L for the placebo group compared with 34.2 U/L to 30.3 U/L for naltrexone group; reference range, 10–45 U/L for females and 10–70 U/L for males), but the aspartate aminotransferase (AST) level decreased in the naltrexone group (N=20) and from 57.0 U/L to 65.0 U/L in the placebo group; reference range, 10–35 U/L for females and 10–45 U/L for males; difference between groups, Mann-Whitney U test=145.5, p=0.004), indicating a better outcome among patients receiving naltrexone.

Craving for opioids or amphetamine, as well as HIV-drug and HIV-sex risk behaviors, decreased in both groups over the study period (Figure 2). However, no significant differences in craving, for either opioids or amphetamine, were observed between the groups.

Discussion

Our results show that relative to placebo, the naltrexone implant resulted in higher retention in the study, decreased heroin and amphetamine use, and improved clinical condition of patients, thus providing the first evidence of an effective pharmacological treatment for this type of polydrug dependence. Because the majority of drug-dependent patients use more than one drug (17), treatment of only one dependence, such as intravenous heroin use by oral methadone or buprenorphine, would not be sufficient for injection-related harm reduction if the patient continued to inject other drugs, such as amphetamine. Since long-acting naltrexone effectively decreases opioid use, it might lead to compensatory increases in the use of nonopioid drugs, such as amphetamine, among polydrug-dependent patients, resulting in zero net benefit. However, our results indicate that this is not the case. The effectiveness of polydrug dependence treatment with naltrexone implants or depot injections should be studied and confirmed in other patient populations who use combinations of heroin, buprenorphine, amphetamine, and cocaine. Preliminary evidence from a study by Comer et al. (15) suggests that naltrexone depot formulations might have a beneficial effect on cocaine abuse and even on cannabis and benzodiazepine abuse. This suggests that the opioidergic system may be the common pathway for the effects of all these drugs of abuse. A recent meta-analysis that included 10 randomized controlled trials comparing oral naltrexone and placebo detected no beneficial effect on retention or relapse rates for opioid-dependent patients (24). However, a significant treatment effect was observed in a Swedish study (19) that compared oral naltrexone and placebo in the treatment of amphetamine dependence in selected and highly motivated patients (more than 70% of the assessed individuals were excluded from the study). In the present study, our sample was a typical treatment-seeking patient population (only 16% of assessed individuals were excluded), which suggests that our results reflect the real-world effectiveness of the naltrexone implant treatment. The duration of our trial was 10 weeks, which is a short period when considering the chronic nature of concurrent opioid and amphetamine dependence. It is likely that in clinical practice, patients...
should be treated with several successive implants in 2- to 3-month intervals to achieve long-term recovery from dependence.

The naltrexone implant was generally well tolerated. It was not associated with increased levels of ALT or AST, and it was actually associated with a reduction in AST levels compared with placebo. Two patients (4%) experienced mild surgical side effects. The implant used in this study results in naltrexone serum levels of around 2 ng/mL for 10 weeks, which is somewhat higher than levels provided by the currently available depot injection (Vivitrol) during 4-week injection intervals (25). Vivitrol has been shown to be effective for the treatment of heroin dependence, and it was recently approved by the U.S. Food and Drug Administration for the treatment of opioid dependence. However, whether it is also effective for the treatment of amphetamine dependence is unknown.

It has been suspected that oral naltrexone treatment could lead to an increased risk of death due to accidental overdose (26). However, a large follow-up study (27) that included all patients in Western Australia starting methadone (N=553) or naltrexone implant (N=341) found that naltrexone implant was associated with a slightly lower age-standardized mortality rate ratio compared with methadone (0.65, 95% CI=0.12–1.17). This suggests that while oral naltrexone may be ineffective in treating opioid dependence, because of low treatment adherence and the increased risk of concomitant opioid overdose, a naltrexone implant is at least as safe as methadone. In our study, no deaths were reported in the survey of all patients at the end of the study.

Received July 27, 2011; revisions received Aug. 25 and Nov. 28, 2011; accepted Dec. 5, 2011 (doi: 10.1176/appi.ajp.2011.11071121). From the Department of Forensic Psychiatry, University of Eastern Finland, and Niuvanniemi Hospital, Kuopio, Finland; the Department of Clinical Physiology, Kuopio University Hospital, Kuopio; the Finnish Medicines Agency, Kuopio; the Department of Mental Health and Alcohol Research, National Institute for Health and Welfare, Helsinki; the Helsinki Deaconess Institute, Helsinki; the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm; the St. Petersburg Bekhterev Psychoneurological Research Institute and Valdman Institute of Pharmacology, St. Petersburg Pavlov State Medical University, St. Petersburg, Russia. Address correspondence to Dr. Tiihonen (jari.tiihonen@niuvu.fi or jari.tiihonen@ki.se).

Dr. Tiihonen has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Hoffman-La Roche, Janssen-Cilag, Lundbeck, and Organon, has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, and has received lecture fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Novartis, and Pfizer. Dr. Krupitsky has served as a consultant to Alkermes. The other authors report no financial relationships with commercial interests.

Funded by the Finnish Ministry of Health and Social Affairs, the Finnish National Institute for Health and Welfare, and the Academy of Finland. The funders were not involved in the conduct of the study or in collection, management, analysis, or interpretation of the data. ISRCTN (www.controlled-trials.com) registry number ISRCTN8905555.

### References


